Compare Heron Therapeutics Inc (HRTX) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Okta, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Okta, Inc. trades at $147.83 (market cap $25.79B). The key difference: Okta, Inc. is far larger — about 282× Heron Therapeutics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | OKTA | |
|---|---|---|
Market Cap | $91.46M | $25.79B |
Sector | Health | Technology |
52-Week High | $1.96 | $154.62 |
52-Week Low | $0.39 | $62.93 |
Enterprise Value | $189.36M | $23.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
OKTA trades at $150.64, up 0.86% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.96. Revenue growth accelerated to $2.61B in 2025, achieving positive net income of $28M after years of losses, while operating cash flow surged to $750M. Recent news highlights AI-driven cybersecurity demand boosting Okta's identity protection solutions.
Outlook is positive given earnings momentum and sector tailwinds, but high valuation multiples (P/E 108.22) pose risks if growth slows. Analyst consensus is strongly bullish with a $125.78 price target, though competitive pressures and macroeconomic volatility remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
